European Health Union: green light for two new COVID-19 therapeutics

European Health Union: green light for two new COVID-19 therapeutics

On Thursday, the European Medicines Agency (EMA) has given a positive opinion on two COVID-19 treatments — Ronapreve and Regkirona — identified by the Commission as promising therapeutics under the EU Strategy on COVID-19 Therapeutics. Both are treatments for use during the early stages of infection based on antiviral monoclonal antibodies.

Welcoming this important progress under the Strategy, Commissioner for Health and Food Safety, Stella Kyriakides, made the following statement:

The EU Therapeutics Strategy aims to build a broad portfolio of COVID-19 therapeutics with the goal of having three to five new therapeutics available by the end of the year. It covers the full lifecycle of medicines from research, development, selection of promising candidates, fast regulatory approval, manufacturing and deployment to final use.

A first list of five promising therapeutics was published in June 2021. In October 2021 the Commission delivered on a key action by establishing a portfolio of 10 potential COVID-19 therapeutics. The list established is based on independent scientific advice, and focuses on COVID-19 treatment candidates that are likely to be authorised and therefore available on the European market soon. These therapeutics will bring treatment to patients across the EU as fast as possible provided that their safety and effectiveness has been confirmed by the European Medicines Agency. Both Ronapreve and Regkirona were included in the Commission’s list of five promising therapeutics in June 2021 and applied for marketing authorisation in October 2021.

The Strategy forms part of a strong European Health Union, using a coordinated EU approach to better protect the health of our citizens, equip the EU and its Member States to better prevent and address future pandemics, and improve resilience of Europe’s health systems.

On Top